Literature DB >> 12638389

Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Honghui Zhou1.   

Abstract

Drug absorption is a very complex process that manifests itself through potential interaction with a host of physicochemical and physiological variables. Some factors that may affect the absorption processes include presystemic metabolism/efflux, the "absorption window" along the gastrointestinal tract, disease states, demographics (gender, age, ethnicity), and biopharmaceutical classification of solid dosage forms. Despite the complexity of the absorption processes, the analysis of the absorption kinetic data is mostly empirical, and the assumption of first-order absorption is axiomatic. Nevertheless, we often encounter irregular drug absorption profiles (such as double-peak, absorption window-type absorption profiles, etc.) that cannot be satisfactorily described by a simple first-order absorption process. The selection of an inappropriate absorption model would result in the misspecification of the pharmacokinetic model and subsequent erroneous prediction of the dosing regimen. This article presents several pharmacokinetic strategies in analyzing typical and atypical absorption profiles. The atypical absorption profiles discussed in this article include parallel first-order absorption, mixed zero-order and first-order absorption, Weibull-type absorption, absorption window with or without Michaelis-Menton absorption, time-dependent absorption, and inverse Gaussian density absorption. In any event, intravenous drug concentration-time data are generally needed to avoid the ambiguousness in the absorption analyses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12638389     DOI: 10.1177/0091270002250613

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  41 in total

1.  Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch.

Authors:  Matthew W Linakis; Joseph E Rower; Jessica K Roberts; Eleanor I Miller; Diana G Wilkins; Catherine M T Sherwin
Journal:  Br J Clin Pharmacol       Date:  2017-09-06       Impact factor: 4.335

2.  Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs.

Authors:  M N Martinez; B Mistry; V Lukacova; K A Lentz; J E Polli; S W Hoag; T Dowling; R Kona; R M Fahmy
Journal:  AAPS J       Date:  2017-03-06       Impact factor: 4.009

Review 3.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

4.  The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.

Authors:  Chantal Csajka; David Drover; Davide Verotta
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

5.  A note on population analysis of dissolution-absorption models using the inverse Gaussian function.

Authors:  Jian Wang; Michael Weiss; David Z D'Argenio
Journal:  J Clin Pharmacol       Date:  2008-03-21       Impact factor: 3.126

6.  Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).

Authors:  Jun Shen; Alison Boeckmann; Andrew Vick
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-04       Impact factor: 2.745

7.  Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.

Authors:  Elena Soto; Sebastian Haertter; Michael Koenen-Bergmann; Alexander Staab; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2009-12-29       Impact factor: 4.200

8.  Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Authors:  Lien Ngo; Hee-Doo Yoo; Phuong Tran; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-18       Impact factor: 2.745

9.  Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.

Authors:  Josef A Vogt; Christian Denzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-02       Impact factor: 2.745

10.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.